RXi Names Inflammatory Disease as Lead Program; Neurological Disease Slips Off Radar

The company also noted in a filing with the US Securities and Exchange Commission that it continues to seek out industry partnerships after having failed to forge a deal in 2008 as previously anticipated.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.